Indications of durvalumab/Infinifer

Durvalumab/Durvalumab is a new type of immune checkpoint inhibitor that mainly restores the immune activity of T cells by blocking the PD-L1 and PD-1 pathways, thereby achieving sustained attack on tumor cells.

In non-small cell lung cancer ( NSCLC), durvalumab is suitable for multiple stages of treatment. For resectable NSCLC patients with tumors ≥4 cm or positive lymph nodes, platinum-containing chemotherapy can be used as a neoadjuvant regimen first, and single-agent adjuvant therapy can be continued after surgery. The effect is more accurate especially in patients without EGFR or ALK gene driver abnormalities. For unresectable stage III NSCLC, patients who have not progressed after receiving concurrent chemoradiotherapy can continue to use durvalumab maintenance therapy. This model has been regarded as one of the standard regimens for locally advanced NSCLC. In addition, it can be combined with temtumumab and platinum-containing chemotherapy for metastatic NSCLC and is suitable for patients without EGFR or ALK sensitizing mutations.

In small cell lung cancer (SCLC), the indications of durvalumab also cover the limited stage and extensive stage. Patients with limited-stage SCLC who have not progressed after concurrent chemoradiotherapy can be maintained with durvalumab alone, while extensive-stage SCLC is often combined with etoposide plus platinum drugs as first-line treatment, which significantly improves the patient's survival expectation.

Among digestive system tumors, biliary tract cancer is a direction with significant benefits. Imrvalumab combined with gemcitabine and cisplatin has been proven to be useful in locally advanced or metastatic biliary tract cancer, providing a new option for this rare disease with limited treatment options. At the same time, in the field of hepatocellular carcinoma, durvalumab can be combined with temsilimumab for the treatment of unresectable liver cancer, becoming an important part of immunotherapy combination therapy.

In the field of gynecological oncology, durvalumab also shows unique value. For primary advanced or recurrent endometrial cancer with mismatch repair deficiency (dMMR), durvalumab can be combined with carboplatin and paclitaxel, followed by continued monotherapy, to help patients achieve longer survival.

Reference materials:https://www.imfinzi.com/